Mexican Delphi Consensus to Use Favipiravir in Patients with COVID 19 (Expert Panel)
Publicaciones de socios | Comisión de investigación
Otras publicaciones
Fecha de publicación
02/10/2023
Autores
Herrera Garcia Jose Carlos, Colli Domínguez Andrea A, Galicia Sánchez Luz M, Vazquez Cortés Jesús J, Buenfil Gómez Carlos M, Cuilty Siller Carlos, López Sánchez Guillermo N, López de Lara Díaz Agustín, Casillas Suárez Catalina, and Bringas locela Erick W
Área de la especialidad
Datos bibliográficos
Herrera García José Carlos*, Colli Domínguez Andrea A, Galicia Sánchez Luz M, Vazquez Cortés Jesús J, Buenfil Gómez Carlos M, et al. Mexican Delphi Consensus to Use Favipiravir in Patients with COVID 19 (Expert Panel). Am J Biomed Sci & Res. 2023 20(1) AJBSR. MS.ID.002677, DOI: 10.34297/AJBSR.2023.20.002677
Received: September 11, 2023; Published: September 20, 2023
Abstract
The SARS COV2 pandemic in 2020 associated with severe pneumonia has been the most prevalent clinical entity in the morbidity and mortality of the disease. New antiviral treatments have been used under different emergency protocols with the aim of reducing the spread of the virus and reducing its lethality. Since 2013, favipiravir is an antiviral used to treat resistant influenza. Recently, multiple studies in Japan, Russia and China have demonstrated its effectiveness under the inhibitory mechan